AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
British Bio-technology, Oxford, United Kingdom, announced a development in the progress of its AIDS treatment, p24-VLP.
Following a successful Phase I trial, a pilot Phase II trial started December 10, 1992, in HIV-positive patients. This is the first time that p24-VLP has been tested in HIV-positive subjects.
The pilot study is designed to test tolerability in HIV-positive subjects. The trial is being conducted at St. Mary's Hospital, Paddington, London, a United Kingdom AIDS center, under the direction of Professor Jonathan Weber.
p24-VLP, an immunotherapy, is designed to slow down or prevent the onset of AIDS in HIV-positive subjects. …